Showing 81 - 100 results of 2,033 for search '"Pharmacoeconomics"', query time: 0.34s Refine Results
  1. 81
  2. 82
  3. 83
  4. 84

    The issues of safety and pharmacoeconomics in the management of chronic pain in the back and limbs by Vladimir Anatol'evich Parfenov, O N Gerasimova, Vladimir Anatolyevich Parfenov, O N Gerasimova

    Published 2011-06-01
    “…The paper reviews the data available in the literature on adverse reactions occurring with the use of NSAIDs, discusses the issues of pharmacoeconomics in the administration of various NSAIDs. …”
    Get full text
    Article
  5. 85
  6. 86
  7. 87

    PHARMACOECONOMICS AS A TOOL TO ENHANCE EFFICENCY OF HEALTH CARE SERVICES by Denys Zakrytov, Navneet Kaur

    Published 2017-11-01
    “…Pharmacoeconomics identifies, measures, and compares the costs and consequences of drug therapy to health care systems and society. …”
    Get full text
    Article
  8. 88
  9. 89
  10. 90
  11. 91

    Pharmacoeconomic analysis of alogliptin use in the treatment of type 2 diabetes by S. V. Nedogoda, I. N. Sorokina, A. S. Salasiuk, V. O. Smirnov

    Published 2018-05-01
    “…Aim of the study: Determine the validity of alogliptin choice in comparison with other DPP-4 inhibitors, available in Russia (saxagliptin, linagliptin, vildagliptin, sitagliptin) for add-on treatment in patients with inadequate glycemic control on metformin monotherapy, basing on pharmacoeconomic analysis Methodology. Retrospective modeling was performed according to standard pharmacoeconomic methods: cost-minimization analysis, cost-effectiveness analysis (CEA), cost-utility analysis (CUA) and sensitivity analyzes. …”
    Get full text
    Article
  12. 92
  13. 93
  14. 94
  15. 95
  16. 96
  17. 97
  18. 98

    Pharmacoeconomic analysis of botulinum toxin in complex therapy for cerebral palsy by A. S. Kolbin, I. A. Vilum, M. A. Proskurin, Yu. E. Balykina

    Published 2018-06-01
    “…We have performed the fi rst-ever pharmacoeconomic analysis in a Russian context of botulin toxin drugs as part of combined therapy for juvenile cerebral palsy (JCP) compared to standard clinical practice. …”
    Get full text
    Article
  19. 99
  20. 100